News FDA backs Glenmark's rival to AZ's blockbuster Farxiga AstraZeneca’s diabetes drug Farxiga could face generic competition in the US, after the FDA gave tentative approval to a generic rival from India’s Glenmark, although it is unclear when the
News Sources quash rumours of an AZ/BMS mega-merger A media report suggests there is no substance to the rumours of a $400 billion mega-merger between AstraZeneca and Bristol Myers Squibb.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
